Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Trump unveils deal to expand coverage and lower costs on obesity drugs

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand ...

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of ...

Eli Lilly, Novo to cut GLP-1 cost; airline stocks fall on FAA cut

Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly ...

Eli Lilly's next generation weight loss drug shows promise, early trial results suggest

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Eli Lilly, Novo Nordisk negotiating deal with Trump administration on obesity drug prices

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Eli Lilly partners with Walmart to sell weight loss drug directly to patients nationwide

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly to invest in a $3B manufacturing facility in Netherlands

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

Trump announces deal with Novo Nordisk and Eli Lilly

President Donald Trump announces an agreement with drugmakers Novo Nordisk and Eli Lilly to lower the cost of their GLP-1 ...

Eli Lilly expects US FDA approval for oral obesity drug in March 2026

Food and ⁠Drug ‌Administration to approve ‍its experimental oral obesity drug,​ ‌orforglipron, by March 2026, its ⁠chief executive ​said ​on Thursday. (Reporting ‍by ⁠Kamal Choudhury in Bengaluru;⁠ ...